We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Technique Rapidly Detects Needle-in-a-Haystack Plasma Biomarkers for Disease Diagnosis

By LabMedica International staff writers
Posted on 12 May 2023
Print article
Image: New method enables detection of plasma biomarkers cheaply and at scale (Photo courtesy of Freepik)
Image: New method enables detection of plasma biomarkers cheaply and at scale (Photo courtesy of Freepik)

Blood plasma, routinely collected during medical care and research, has the potential to be an abundant source of protein biomarkers. These markers can serve diagnostic and prognostic roles, measure treatment response, and provide insights into disease biology. However, finding such biomarkers in plasma using proteomics, the most advanced tool currently available, is challenging. This is because 99% of plasma is composed of common proteins like albumin, globulins, and coagulants that essentially hide potential biomarkers. These same proteins are repeatedly identified in a plasma sample, making the detection of the less abundant but interesting proteins difficult. While scientists have attempted to remove these common proteins from plasma samples using antibodies, the process has been found to be costly, time-consuming, and not robust enough for large-scale usage. Now, a team of researchers has developed a new, rapid, and cost-effective method to remove these proteins by repurposing an old biochemical technique from 1948.

Researchers at Boston Children's Hospital (Boston, MA, USA) came upon a technique previously mentioned in literature on protein and peptide studies that could be applied to plasma. During the COVID-19 pandemic, the researchers were tasked with analyzing the proteins in 5,000 plasma samples for a study looking at immune responses in about 1,100 hospitalized COVID-19 patients. This task had to be accomplished at a time when many labs were closed due to the pandemic. In a span of three months, the researchers had to develop a method to analyze ten times the amount of plasma samples than they typically handled daily. The team successfully accomplished this task, and their work contributed to the identification of tissue- and organ-specific biomarkers, which accurately predicted the progression of hospitalized COVID-19 patients.

This new technique employs perchloric acid, a very potent superacid, along with very low temperatures (-20°C) to separate the common proteins within as little as 15 minutes, without harming the remaining proteins. The unwanted proteins coagulate similar to how milk curdles in lemon juice. The samples can then be centrifuged, and the liquid at the top, which contains the required proteins, can be collected. This method is fast enough for large-scale use, depleting the unwanted proteins at a cost of only USD 2.50 per sample, significantly lower than current costs. This technique enables the detection of over 1,500 proteins per sample at a rate of 60 samples per day.

Related Links:
Boston Children's Hospital 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.